News

Public · Published

Canaccord Genuity maintains Ultragenyx Pharmaceutical at Buy, lowers price target to $34 from $39

Canaccord Genuity kept its Buy rating on Ultragenyx Pharmaceutical but cut its price target to $34 from $39, a 12.8% decrease. The article says the new target implies 98.1% upside from the November 4 closing price of $17.16.

Published:

Updated:

What happened

Canaccord Genuity kept its Buy rating on Ultragenyx Pharmaceutical but cut its price target to $34 from $39, a 12.8% decrease. The article says the new target implies 98.1% upside from the November 4 closing price of $17.16.

Confirmed

Global impact / market context

The lower target signals that Canaccord sees less potential value than before, even while retaining its Buy rating. A price target is an analyst’s estimate, not a promised share price; the article provides no company operating news to explain the change.

Analyst inference

The target remains above the November 4 close, but the five other recent analyst targets listed range from $17 to $22. That contrast shows Canaccord’s estimate is an outlier in this small set, rather than a shared view among the listed analysts.

Analyst inference

What to watch

  1. Check whether Canaccord publishes further changes to its rating or target, since the article records a lower estimate but gives no reason for the revision. Analyst inference
  2. Compare future analyst targets with the listed $17–$22 range; a widening or narrowing gap would show whether views are becoming more aligned. Analyst inference
  3. Look for company updates on revenue, costs, or cash available that could provide operating evidence behind later changes in analysts’ estimates. Analyst inference

Evidence

  • Original source link unavailable